Mu-opioid receptor–cannabinoid receptor 1 heteromer (MOR–CB1 heteromer)

The **mu-opioid receptor–cannabinoid receptor 1 heteromer** is a macromolecular complex formed by the physical association of the mu-opioid receptor (MOR) and the cannabinoid receptor 1 (CB1), both of which are G protein-coupled receptors primarily expressed in the central and peripheral nervous system. Heteromerization confers unique ligand binding, signaling, and trafficking properties distinct from those of the individual receptors. In neuronal tissue, this heteromer modulates analgesia, reward, and dependence pathways, displaying both synergistic and antagonistic interactions between opioids and cannabinoids[2][3][4][6][7]. It is considered a promising therapeutic target for pain management and addiction, as drugs targeting the heteromer may offer improved analgesic efficacy with reduced risk of tolerance and dependence[2][4]. Research into the MOR–CB1 heteromer is ongoing, with particular interest in developing bivalent ligands and other strategies to exploit its distinct pharmacology for safer and more effective treatments.

Other names

Mu-opioid receptor–CB1 receptor heteromerMOR–CB1 receptor complexμ-opioid receptor–CB1 receptor heteromermu–CB1 heteromer

Allosteric modulation (heteromerization leads to altered signaling properties compared to individual receptors)[6] Synergistic or antagonistic effects on analgesia, reward, and signaling (e.g., co-activation modulates G-protein coupling and second messenger responses)[6] Modulation of tolerance development and dependence (potential to affect opioid tolerance/withdrawal)[7] Cross-inhibition of signaling pathways (e.g., Src-STAT3 inhibition with co-activation)[3]